Linkedin Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.

Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.

Webinar presenter Jeffrey Gregg, MD, University of Nevada

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.

Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, December 9, 2026, 12 PM-1 PM ET
Hear an expert pathologist discuss the role of HER2 IHC testing and scoring in solid tumors including endometrial, ovarian, cervical, bladder, non-small cell lung, colorectal, and biliary cancers

Webinar presenter Michelle Shiller, DO, MSPT, Baylor Sammons Cancer Center; Fulgent Genetics; Texas Cancer Interception Institute

CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Manage Subscription

To receive CAP TODAY magazine, please subscribe here.
For change of address, mail new information to: CAP TODAY Circulation, 325 Waukegan Road, Northfield, IL 60093-2750 or visit here.

Columns

Molecular pathology selected abstracts

January 2025—Autism spectrum disorder is a neurodevelopmental disorder that has behavioral and social effects. Average patient age at diagnosis is approximately five years old. However, symptoms can appear within the first 12 months of life. The symptoms and severity of autism spectrum disorder (ASD) vary widely. They can include difficulty with verbal and nonverbal societal interaction, limited or repetitive behaviors, varying intellectual abilities, and emotional dysregulation.

Q&A column

January 2025
Q. In a CAP TODAY Q&A (published in August 2024), it was stated that a correlation between an automated and manual white blood cell count is not needed in clinical practice. Does this apply to digital imaging analyzers, such as those from CellaVision and Scopio, as well? If correlations between digital and manual differentials are required, what are your recommendations for acceptability? Read answer.

Q. When we write pathology reports, especially for prostatectomies, our diagnostic lines are often long, per CAP checklist requirements. In some cases, we retrim the surgical margins to evaluate the distal margins and note in the diagnostic line that margins will be studied further. When we report the margin status after retrimming, we are compelled to amend the report, leading to a large and somewhat confusing report because our long diagnostic lines are repeated; the only difference is the single line of the surgical margin. Do you have recommendations for creating an amended versus addendum report and addressing how the report can be more focused for clinicians and patients? Read answer.

Newsbytes

January 2025—NYU Langone Health, a New York-based multisite system with six inpatient facilities, is implementing digital pathology—some would say lightning quick considering its size. Having started the project in mid-October with six subspecialties, pathology services expects to fully implement the digital distribution of images systemwide by this spring. “What we’ve seen at other systems is a very slow transition that sometimes never gets accomplished to 100 percent,” says Joan Cangiarella, MD, vice chair of clinical operations, Department of Pathology, NYU Grossman School of Medicine. “Here we presented it as, ‘We are all going to go digital.’”

Put It on the Board

January 2025—The biochemical genetics and molecular technologies laboratories at Mayo Clinic in Rochester, Minn., reported in a recently published study that individuals with a TPMT*1/*8 diplotype displayed reduced thiopurine 6-mercaptopurine metabolism between that of normal metabolizers and intermediate metabolizers, suggesting that TPMT*8 is a reduced-function allele. That allele is common among individuals of African or African American ancestry (approximately 2.3 percent minor allele frequency), the authors write, but is not included in genotyping recommendations owing to its uncertain function.

From the President’s Desk

December 2024—Maybe you’ve had this experience: A patient calls, scared to death. They can’t reach their doctor and they can’t make sense of their pathology report. What they want to know is simple: What does it mean for my health? Now that pathology reports and lab results are going to many patients at the same time they’re released to ordering physicians, we pathologists have a new audience to keep in mind. It’s a major change in who’s reading our reports and how familiar they are with the terminology we use. (Let’s face it: Our reports read like Greek even to our fellow physicians. They must be downright mystifying to patients.)

Clinical pathology selected abstracts

December 2024—Excitement over the impact of artificial intelligence-based tools in different areas of health care has prompted position papers and research on the application of these new devices. One such tool is ChatGPT, which is publicly available and has demonstrated domain-specific knowledge in numerous areas, including medicine. The vast amount of data generated with current technologies, including digital pathology applications, and in subspecialty areas of pathology may lend itself to interpretation with artificial intelligence-based algorithms. But while AI-based applications can automate routine tasks and enhance diagnostic accuracy, their widespread use has been limited. Further AI research and validation of AI-based applications will increase adoption of such technology and, thereby, the overall efficiency and accuracy of the diagnostic process in pathology.

Anatomic pathology selected abstracts

December 2024—Recurrence of Crohn’s disease within one or two years of resection is common. The authors conducted a study in which they sought to identify histologic features in Crohn’s disease resections that may predict earlier recurrence (18 months or less) to potentially guide postoperative management. They performed a single-institution, retrospective database review of 41 patients who had first-time Crohn’s disease bowel resection specimens collected between October 2002 and December 2007. Patient demographics and Crohn’s disease course were documented. Slides were reviewed for the distribution and composition of inflammation, small bowel pyloric metaplasia, and the presence and characteristics of submucosal fibrosis and granulomas.

Molecular pathology selected abstracts

December 2024—Acute promyelocytic leukemia is generally characterized by presence of the PML::RARA fusion. However, a subset of cases with morphological, cytochemical, and immunophenotypic features of acute promyelocytic leukemia (APL) lack this canonical fusion gene and instead present with alternate fusions. These include RARA fusions with partners other than PML and fusions involving other retinoic acid receptor (RAR) genes, such as RARG. Leukemias with these variant fusions often resist all-trans retinoic acid (ATRA) therapy. Specifically, the ATRA sensitivity of RARA fusion genes varies based on its 5′ fusion partner. Interestingly, in some studies, the artificially induced variant RAR bipartite fusion genes responded well to ATRA.

Newsbytes

December 2024—In a casual water cooler conversation, while standing around a coagulation analyzer to be precise, Lisa Daniel listened to her laboratory colleagues and a hospitalist, who happened to stop by the department, discuss their frustration with duplicate and other unnecessary tests. This led her to start a small committee, which in eight years has sextupled in size and undertaken numerous cost-saving measures.

Q&A column

December 2024
Q. What are the preferred tests for chronic kidney disease (CKD) screening and classification? Read answer.
Q. Is there a formula to correct a white blood cell count for micromegakaryocytes, or are megakaryocytes considered clinically insignificant unless there are greater than five per 100 WBCs? Is there a movement to drop reporting percents for individual WBCs, reactive lymphocytes, and reticulocytes? If so, does the CAP support such a change? Read answer.

MARKETPLACE

TRENDING